Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

Novo Nordisk A/S (NYSE:NVO) is one of the stocks that Jim Cramer shed light on. A caller asked about the stock’s status, and Cramer replied: “I want you to know I don’t want Novo Nordisk… and the ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ending of its deal with Hims & Hers jeopardizes the healthcare platform's ...

The breakup between Novo Nordisk and Hims & Hers remains acrimonious. Recent remarks highlight the competition facing Novo Nordisk's Wegovy. On Monday, Novo Nordisk terminated the partnership ...

Novo Nordisk is partnering with WeightWatchers to offer consumers access to Wegovy after it abruptly ended its collaboration with Hims & Hers.

June 26 (Reuters) - Novo Nordisk (NOVOb.CO) said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical giant that is a key player in the weight loss drug market. The firm’s shares have lost 15.7% year-to-date.